Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
04:05pm, Wednesday, 01'st May 2024
MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat sever
NEW YORK, NY / ACCESSWIRE / April 25, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Corcept Therapeutics Incorporated (NAS
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Wednesday, 24'th Apr 2024
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
01:16pm, Tuesday, 23'rd Apr 2024
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Corcept Therapeutics Incorporated (NAS
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Wednesday, 17'th Apr 2024
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for April 17th
08:30am, Wednesday, 17'th Apr 2024
BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
Corcept (CORT) Completes Enrollment in Phase II ALS Study
12:35pm, Tuesday, 16'th Apr 2024
The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Corcept Therapeutics Incorporated (NAS
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
12:11pm, Tuesday, 09'th Apr 2024
The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome
08:00am, Monday, 01'st Apr 2024
MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat sev
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
11:20am, Monday, 25'th Mar 2024
Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
02:36pm, Friday, 16'th Feb 2024
Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript
09:50pm, Thursday, 15'th Feb 2024
Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
04:07pm, Thursday, 15'th Feb 2024
MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve
